Lee 2011 [13]
|
SC retrospective PS-matched case- control study
|
South Korea
|
2004–2009
|
CFZ
|
49
|
NR
|
17
|
NR
|
30-day over mortality
|
NAF
|
84
|
NR
|
15
|
NR
|
90-day SAB-related mortality
|
Paul 2011 [14]
|
SC retrospective cohort study
|
Israel
|
1988–1994 & 1999–2007
|
CFZ
|
72
|
NR
|
NR
|
5.2
|
30-day all-cause mortality
|
CLX
|
281
|
NR
|
NR
|
90-day mortality
|
Renaud 2011 [15]
|
SC retrospective cohort study
|
Singapore
|
2009
|
CFZ
|
14
|
2
|
NR
|
NR
|
30-day mortality
|
CLX
|
13
|
2–8
|
NR
|
NR
|
Li 2014 [16]
|
MC retrospective cohort study
|
USA
|
2008–2012
|
CFZ
|
59
|
6
|
31
|
7
|
30-day all-cause mortality
|
OXA
|
34
|
12
|
39
|
18
|
90-day all-cause mortality
|
Bai 2015 [17]
|
MC retrospective PS-matched cohort study
|
Canada
|
2007–2010
|
CFZ
|
105
|
3
|
NR
|
10
|
90-day mortality
|
CLX
|
249
|
12
|
NR
|
18
|
Rao 2015 [18]
|
MC retrospective cohort study
|
USA
|
2010–2013
|
CFZ
|
103
|
6
|
29
|
41.8
|
All-cause in-hospital mortality
|
OXA
|
58
|
12
|
32.5
|
32.8
|
Pollett 2016 [19]
|
SC prospective PS-matched cohort study
|
USA
|
2008–2013
|
CFZ
|
70
|
NR
|
20
|
13
|
90-day all-cause mortality
|
NAF
|
30
|
NR
|
12
|
27
|
Flynt 2017 [20]
|
MC retrospective cohort study
|
USA
|
2013–2015
|
CFZ
|
68
|
6
|
NR
|
NR
|
30-day all-cause mortality
|
NAF
|
81
|
12
|
NR
|
NR
|
McDanel 2017 [21]
|
MC retrospective cohort study
|
USA
|
2003–2010
|
CFZ
|
1163
|
NR
|
NR
|
15
|
30-day all-cause mortality
|
NAF/ OXA
|
2004
|
NR
|
NR
|
19
|
90-day all-cause mortality
|
Lee 2018 [22]
|
MC prospective PS-matched cohort study
|
South Korea
|
2013–2015
|
CFZ
|
79
|
NR
|
NR
|
NR
|
90-day all-cause mortality
|
NAF
|
163
|
NR
|
NR
|
NR
|
30-day all-cause mortality
|